New York, April 12, 2024 - PRISM MarketView - NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) has announced that doctors at a top-ranked US hospital have successfully performed the first implant of the company’s OneRF™ Ablation Evo® sEEG-RF electrode. NeuroOne’s OneRF™ Ablation system is a thin film stereoelectroencephalography (sEEG)-guided radiofrequency (RF) system and is designed for recording electrical activity and ablating nervous tissue using a single electrode.
“We are excited to announce that yesterday, doctors implanted Evo® sEEG-RF electrodes in a patient suffering from epilepsy. Once the monitoring identifies the areas of the brain that are causing seizures, the surgical team now has the option to use the same electrodes to perform an ablation utilizing NeuroOne’s RF generator. This capability provides the neurosurgeon an entirely new option for use in the appropriate patients and situation.”
NeuroOne CEO, Dave Rosa
Being first to market with this technology positions NeuroOne as a market leader in offering multi-functional diagnostic and therapeutic thin-film electrode technology. The company believes that its technology has the potential to reduce hospital stays, number of surgeries, and adverse events, while offering significant clinical benefits – including temperature controlled ablation – to enhance patient safety.
Last month, NeuroOne initiated a limited commercial launch of its OneRF™ Ablation system, shipping systems to participating centers in March and beginning patient treatments in April.
Highlights
The OneRF™ Ablation system has FDA 510(k) clearance for creation of radiofrequency lesions in nervous tissue for functional neurosurgical procedures.
NeuroOne has developed a full line of thin film electrode technology for diagnostic brain mapping procedures and RF ablation.
The company’s other FDA-cleared devices include the Evo® cortical and sEEG electrode product lines which are used for stimulation, recording and monitoring of electrical activity in the brain.
NeuroOne estimates the rapidly growing current brain ablation market to be valued at approximately $100 million worldwide.
About NeuroOne
NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence solutions. For more information, visit www.nmtc1.com.
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) is featured on PRISM Emerging MedDevices Index
About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on Twitter.
Disclaimer:
PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
Prism MarketView | Stock Market News & Investment Opportunities
PRISM MarketView - Social Media (X)